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Abstract
Introduction: Genetic factors predisposing individuals to cancer remain elusive in the majority of patients with a
familial or clinical history suggestive of hereditary breast cancer. Germline DNA copy number variation (CNV) has
recently been implicated in predisposition to cancers such as neuroblastomas as well as prostate and colorectal
cancer. We evaluated the role of germline CNVs in breast cancer susceptibility, in particular those with low
population frequencies (rare CNVs), which are more likely to cause disease.”
Methods: Using whole-genome comparative genomic hybridization on microarrays, we screened a cohort of
women fulfilling criteria for hereditary breast cancer who did not carry BRCA1/BRCA2 mutations.
Results: The median numbers of total and rare CNVs per genome were not different between controls and
patients. A total of 26 rare germline CNVs were identified in 68 cancer patients, however, a proportion that was
significantly different (P = 0.0311) from the control group (23 rare CNVs in 100 individuals). Several of the genes
affected by CNV in patients and controls had already been implicated in cancer.
Conclusions: This study is the first to explore the contribution of germline CNVs to BRCA1/2-negative familial and
early-onset breast cancer. The data suggest that rare CNVs may contribute to cancer predisposition in this small
cohort of patients, and this trend needs to be confirmed in larger population samples.
Introduction
It has been estimated that all known cancer susceptibil-
ity genes account for only 1% to 15% of familial cancers
[1,2]. Approximately 5% to 10% of hereditary breast and
ovarian cancers result from dominant mutations in
known single genes [3-6], particularly BRCA1/BRCA2.
Therefore, the basis for a large fraction of genetic pre-
disposition in families with breast and/or ovarian cancer
remains to be uncovered.
Recent studies have highlighted DNA copy number
variation (CNV) as the most prevalent type of structural
variation in the human genome [7-9], and its role in
normal development and disease has been demonstrated
through its impact on gene expression and protein
structure [10-13]. In particular, CNVs involving
deletions have been reported as a cause of cancer sus-
ceptibility, occurring in up to 30% of highly penetrant
cancer-predisposing genes, including BRCA1, BRCA2,
APC, SMAD4 and TP53, as well as mismatch repair
genes [14-16] (reviewed in [17,18]).
Germline gains and losses of large DNA segments
have recently been reported as factors predisposing indi-
viduals to neuroblastoma, prostate and colorectal cancer
and BRCA1-associated ovarian cancer [19-24]. Neverthe-
less, whole-genome CNV profiling of patients fulfilling
criteria for hereditary breast and ovarian cancer, but
without BRCA1/BRCA2 mutations, has not been
reported. In the present study, we investigated the germ-
line CNV profiles of 68 unrelated familial and early-
onset breast cancer patients who were negative for
BRCA1/BRCA2 mutations, with the aim of detecting
new genes contributing to breast and/or ovarian cancer
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Materials and methods
Study approval
The research protocol was approved by the ethics com-
mittee of the AC Camargo Cancer Hospital, São Paulo,
Brazil (protocol 1175/08), and informed consent was
obtained from the subjects.
Patients
Samples of peripheral blood cells for DNA extraction
were collected after informed consent was obtained
from 68 women attending the AC Camargo Cancer
Hospital prior to any systemic treatment. They were
selected for fulfilling at least one of the criteria for her-
editary breast and ovarian cancer published in the
National Comprehensive Cancer Network Practice
Guidelines in Oncology version 1.2010 [25].
Confirmation of the family history of cancer was
obtained whenever possible on the basis of pathology
reports, medical records and/or death certificates. All
women had previously tested negative for BRCA1/
BRCA2 pathogenic mutations (based on Sanger sequen-
cing of coding sequences). Because most of the affected
relatives were already dead, were inaccessible or refused
to participate, we were unable to investigate CNV segre-
gation in the majority of the cases.
The criteria used to select patients, type of cancer, and
age at cancer diagnosis are given in Additional file 1. Most
of the patients (n = 48) were familial cases of hereditary
breast and/or ovarian cancer in which at least one other
family member was affected. The remaining 20 patients
were considered hereditary breast and/or ovarian cancer
patients for being isolated cases of early-onset cancer (≤
45 years of age). Most of the tumors were invasive ductal
breast carcinomas. Aside from two patients who had only
ovarian cancer (patients 9 and 34), all of the other sixty-six
patients had breast cancer (bilateral in patient 67, and
patients 10 and 16 also had ovarian cancer).
Control sample
DNA samples were obtained from the peripheral blood
cells of control participants after their informed consent
was obtained. One hundred DNA samples (seventy-eight
women and twenty-two men) were provided by the
Genetic Center of the Institute of Biosciences, University
of São Paulo, São Paulo, Brazil. They were obtained
from noncarrier relatives of patients affected by mental
impairment with clear genetic etiology unrelated to can-
cer predisposition (namely, fragile × syndrome or de
novo chromosomal rearrangements). No information
regarding their cancer history was available. Age-match-
ing of controls and patients was considered unnecessary
for this study since CNV frequency in blood is generally
considered stable and unrelated to chronological age.
Comparative genomic hybridization based on microarray
(array-CGH)
We performed comparative genomic hybridization based
on microarray (array-CGH) using a 180 K whole-gen-
ome platform (design 22060; Agilent Technologies,
Santa Clara, CA, USA), which has an average probe spa-
cing of 18 kb. Briefly, samples were labeled with Cy3-
and Cy5-deoxycytidine triphosphates by random prim-
ing. Purification, hybridization and washing were carried
out as previously reported [26,27]. Scanned images of
the arrays were processed using Feature Extraction soft-
ware (Agilent Technologies).
We applied the Genomic Workbench software (Agi-
lent Technologies) for calling DNA CNV using the aber-
ration detection method 2 statistical algorithm with a
sensitivity threshold of 6.7. Poor quality hybridization
(QC > 0.3) was disregarded. Duplication or deletion of
genomic segments was considered when the log2 ratio
of the Cy3/Cy5 intensities of a given region encompass-
ing at least three probes was > 0.3 or < -0.3, respec-
tively. All hybridizations were gender-matched and
processed in reverse-labeling duplicates as described
previously [28]. CNVs that were not detected in both
experiments were disregarded.
Copy number validation by real-time PCR
Selected CNVs detected in the patient group were vali-
dated by real-time quantitative PCR (qPCR) [29] using
the SYBR Green system (Roche Applied Science, India-
napolis, IN, USA) on a 7500 Fast Real-Time PCR Sys-
tem apparatus (Applied Biosystems, Foster City, CA,
USA). As controls or for copy number calibration, we
used three DNA samples obtained from healthy donors
and the qPCR values for the GAPD and HPRT genes for
normalization. All samples were run in duplicate, and
the data were analyzed with Microsoft Excel software
(Microsoft Corp, Redmond, WA, USA) using the com-
parative ΔΔCt cycle threshold method (Applied Biosys-
tems), which assumes that the calibrator DNA has two
copies of the control genes.
Data analysis
Detected CNVs were compared to CNV data from oligoar-
ray studies documented in the Database of Genomic Var-
iants (DGV) [30]. We classified the CNVs into “rare” and
“common,” with rare being those that encompassed coding
sequences which had never been documented as variable
in the general population (DGV). CNVs were evaluated
regarding proportion of total and rare CNVs, frequency of
deletions and duplications, length, and gene content using
the Mann-Whitney U test and Fisher’s exact test.
Gene annotation was performed using the University
of California Santa Cruz Genome Browser (UCSC) [31],
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BioMart in the Ensembl Genome Browser [32] and Cat-
alog of Somatic Mutations. We investigated the biologi-
cal features of genes contained within the rare CNVs
using GOTree Machine (GOTM) software [33] to mea-
sure the enrichment in the Gene Ontology (GO) and
Kyoto Encyclopedia of Genes and Genomes (KEGG)
categories. GOTM reports only those enrichments that
are statistically significant as determined by the hyper-
geometric test [34].
Results
Full CNV data on the controls and patients can be
found in Additional file 2. A whole extra copy of the ×
chromosome was identified in one patient. This chro-
mosomal numerical alteration was not considered a
CNV. The array-CGH results are summarized in Table
1. We found a total of 1,238 CNVs in 168 individuals.
CNVs observed in both patient and control samples cor-
responded to 81.3% of the total, all of which overlapped
common CNVs (DGV). CNVs detected exclusively in
one of the groups corresponded to 110 events in
patients and 121 in controls. The distribution of CNVs
did not differ between patients and controls (P = 0.1724,
Mann-Whitney U test).
Only 49 of the 1,238 CNVs could be classified as rare,
and none of them were recurrent. Those CNVs classi-
fied as rare based on DGV data corresponded to 4% (49
of 1,238 CNVs) of all CNVs detected in our study. The
log2 ratios of the rare CNVs (all outside the log2 -0.65
to log2 0.45 range) were not suggestive of mosaicism,
indicating that these CNVs are likely constitutive. In the
control group, 3.28% (23 of 702) of CNVs detected in
23 of 100 individuals (23%) were classified as rare,
whereas 26 of 536 rare CNVs (4.85%) were found in 25
of 68 patients (37%). The median numbers of total and
rare CNVs per genome did not differ between controls
and patients. However, the proportion of rare CNVs in
patients was higher than in the controls (P = 0.0311,
Fisher’s exact test). The relative frequencies of duplica-
tions and deletions among rare CNVs were similar
between controls (14 duplications and 9 deletions) and
patients (14 duplications and 12 deletions).
We also inspected the rare CNVs for length and gene
content (Table 2). The length of rare CNVs in controls
and patients did not differ significantly. The lengths of
rare deletions or duplications did not differ between
patients and controls or within the patient group alone.
However, only in the control group were the deletions
found to be significantly smaller than the duplications
(P = 0.0089, Mann-Whitney U test).
The 26 rare CNVs and the affected genes detected in
patients are described in Table 3. The published litera-
ture regarding those genes already reported to be altered
in cancer is listed in Additional file 3. The rare CNVs
identified in the control group are listed in Additional
file 4. To evaluate whether the rare CNVs detected
among cancer patients represent common CNVs in the
Brazilian population, we compiled CNV data obtained
from independent samples studied in our laboratory
using 180 K array-CGH. These individuals (120 females
and 38 males) were selected on the basis of criteria
other than cancer history, including 52 patients with
dementia, 56 cases of nonsyndromic hearing loss and 51
cases of Müllerian anomalies (C Rosenberg; ACV Kre-
pischi; unpublished data). None of the rare CNVs docu-
mented in this study were detected in these
independent cohorts of patients.
In one family, the patient with early-onset breast can-
cer (patient 3), as well as her affected sister, who pre-
sented with breast cancer at 28 years of age, were found
to carry a 540 kb 1p31.1 microdeletion (Figure 1A). The
heterozygous deletion was confirmed in the two affected
sisters by qPCR. In the second family, a 90 kb microde-
letion at Xq25 was detected in two affected sisters, one
of whom presented with bilateral breast cancer (patient
17).
Figure 1 depicts two additional rare CNVs identified
by array-CGH and validated by qPCR in unrelated
patients. Figure 1B shows a 137 kb deletion at 9p21.3
detected in patient 13. Figure 1C illustrates a 640-kb
duplication mapped at Xq13.1 (patient 27).
We characterized the function of genes located in rare
CNVs in both patients and controls by GO term and
KEGG pathway analysis using the Gene Ontology Tree
Machine. We did not detect any significant difference in
gene content in either patients or controls.
Discussion
We used array-CGH to investigate the role of rare
germline CNVs in probands of individuals with a famil-
ial history of breast and ovarian cancer. Because evalua-
tion of CNV profiles depends on ethnic background,
array platform and method of analysis [35-38], all
experiments were performed using the same platform,
the same analytical parameters and a Brazilian control
group. We disregarded the possibility that the CNVs
Table 1 Summary of DNA copy number variation data
from breast and/or ovarian cancer patients and controlsa
Copy number variation Controls (n =
100)
Patients (n =
68)
Total CNVs 702 536
Rare variants 23 26
Deletions 9 12
Duplications 14 14
Median CNVs per individual
(IQR)b
7.0 (4 to 9) 7.5 (5 to 10)
aCNV = copy number variation. bIQR = interquartile range.
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were somatically acquired because none of the results
were suggestive of mosaicism. Furthermore, the limited
data available indicate that CNV profiles are rather
stable in adult tissues (reviewed in [39]).
Common CNVs often contain cancer-related genes
and likely play a role in carcinogenesis [40]. However,
only a minority of CNVs, those with low population fre-
quencies (rare CNVs), would be likely to contain genes
that are highly penetrant genetic factors for disease sus-
ceptibility, including cancer [7,41]. In our study, the
median numbers of total and rare CNVs per genome
were quite similar in patients and controls, reflecting a
lack of genomic instability in this cohort of patients.
These results are in agreement with data derived from a
study of BRCA1-associated ovarian cancer patients [42].
Nevertheless, the patients did present a higher propor-
tion of rare CNVs compared to controls. None of these
rare CNVs were present in an independent cohort of
more than 150 individuals, providing support for their
nonpolymorphic nature in the Brazilian population.
Assuming that some of these rare CNVs are cancer-
related, the patients would carry an increased cancer
risk proportionate to the number of rare genomic imbal-
ances. The reason why we found a greater proportion of
rare CNVs in patients than in controls is not clear. We
could speculate that deleterious CNVs tend to be
Table 2 Size and gene content of rare copy number variationsa
Rare CNVs Control group (n = 23 CNVs) Patient group (n = 26 CNVs)
Length range (kb) 31 to 684 32 to 1,592
Median size (IQR)b (kb) 225.5 (125.8 to 275.3) 136.7 (70.3 to 278.0)
Deletions (kb) 127.2 (43.7 to 225.5) 145.0 (124.6 to 229.5)
Duplications (kb) 249.5 (202.9.4 to 350.4) 119.2 (50.0 to 278.0)
Gene number/individual 0.4 (44 of 100) 0.8 (57 of 68)
aCNV = copy number variation. bIQR = interquartile range.
Table 3 Genomic positions (build 36-Hg18), size, type and affected genes of the 26 rare copy number variations
identified in patientsa
Chromosome Cytoband Start site Size (bp) CNV type Gene Names Patient
chr1 p31.1 76,801,602 550,723 del ST6GALNAC3, ST6GALNAC5, PIGK 3
chr1 q44 243,610,556 153,230 del KIF26B 16
chr1 p32.1 59,559,568 41,339 del FGGY 15
chr2 p25.1 9,165,985 192,606 del ASAP2 21
chr2 q22.2 143,463,273 300,408 dup KYNU, ARHGAP15 7
chr2 q32.2 190,015,149 45,366 dup WDR75 28
chr3 p24.3 18,759,412 635,060 dup KCNH8, MIR4791 11
chr3 q28 193,405,249 135,458 dup FGF12 1
chr4 q31.3 152,508,270 136,605 del FAM160A1 29
chr6 p12.1 55,468,168 33,031 dup HMGCLL1 30
chr9 p21.3 20,661,515 136,814 del KIAA1797, MIR491 13
chr9 p24.1 5,130,196 168,153 del INSL6, INSL4, RLN2 20
chr9 q31.3 111,832,790 340,164 del PALM2-AKAP2, AKAP2, C9orf152, TXN, TXNDC8, SVEP1 22
chr10 p13 16,970,291 103,018 dup CUBN 19
chr11 q12.3 62,290,497 38,091 dup POLR2G, TAF6L, TMEM179B, TMEM223, NXF1 25
chr16 q23.3 81,315,382 136,618 del CDH13 5
chr16 q11.2 45,058,042 198,742 dup ANKRD26P1, SHCBP1, VPS35 6
chr17 q25.1 71,478,161 33,362 dup ACOX1, TEN1, CDK3 5
chr18 q12.1 27,990,329 64,132 dup MEP1B 18
chr21 q21.3 29,391,572 496,425 del C21orf7, LINC00189, BACH1, GRIK1 8
chr21 q22.3 46,538,913 210,594 dup YBEY, C21orf58, PCNT, DIP2A 12
chrX q22.3 109,193,988 31,659 del TMEM164, MIR3978 23
chrX q25 126,971,799 88,694 del ACTRT1 17
chrX q13.1 68,398,248 639,366 dup FAM155B, EDA 27
chrX p22.31 6,499,677 1,592,274 dup HDHD1, STS, VCX, PNPLA4 15
chrX q13.3 75,294,586 88,796 dup CXorf26 14
aCNV = copy number variation; del = deletion; dup = duplication.
Krepischi et al. Breast Cancer Research 2012, 14:R24
http://breast-cancer-research.com/content/14/1/R24
Page 4 of 8
Figure 1 Rare germline copy number variations detected in three unrelated breast cancer patients. (A) to (C) Top panels exhibit the
array comparative genomic hybridization profiles of the chromosome regions (images based on the Genomic Workbench software) containing
the selected copy number variation (CNV) (left) and the copy number of the corresponding sequences assessed by quantitative PCR in patients
3, 13 and 27 and control individuals (right). Bottom panels show the CNV positions in the chromosomes (small vertical red bars in the
ideograms) and the corresponding genomic segments. The encompassed genes according to the Reference Sequence (RefSeq) collection are
indicated by blue lines in the RefSeq genes track, and the CNVs loci reported in the general population are indicated by the blue (gain) and red
(loss) bars in the Database of Genomic Variants (DGV) Struct Var track (data retrieved from the DGV) (images derived from the UCSC Genome
Browser, freeze October 2011). Part (A) shows microdeletion at 1p31.1 of a 540 kb genomic segment containing the sequences of three genes.
This alteration cosegregated with early-onset breast cancer in patient 3 and her sister. Part (B) shows microdeletion at 9p21.3 of a 137 kb
genomic segment encompassing the gene KIA1797 and the microRNA MIR491 (patient 13). Part (C) shows microduplication at Xq13.1 of a 640
kb genomic segment affecting the FAM155B and EDA genes (patient 27).
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eliminated and, for some reason, conceivably less effi-
cient apoptosis or DNA repair mechanisms, this selec-
tion would be less stringent in these patients. Whatever
the reason may be, the connection between this finding
and the patients’ phenotypes deserves investigation.
Part of the rare genomic imbalances harbors genes
that could potentially affect cancer susceptibility (see
Table 3). For example, a 540 kb microdeletion at 1p31.1
was detected in two affected sisters (Figure 1A). Among
the genes mapped to this deleted segment, the most
relevant to cancer progression is probably ST6GAL-
NAC5, a sialyltransferase recently reported to mediate
breast cancer metastasis to the brain [43]. Another
interesting alteration detected in a patient, an approxi-
mately 137 kb deletion at 9p21.3, encompassed the
KIA1797 and the MIR491 genes (Figure 1B). A germline
CNV affecting this genomic segment was recently
reported in a colorectal cancer cohort [23]. The finding
of a similar 9p21.3 deletion in independent cohorts of
cancer patients strengthens their pathogenic role in can-
cer predisposition.
Our data support the hypothesis that germline DNA
CNV is a genetic factor contributing to breast cancer
predisposition, which is in accord with the findings of
other studies indicating CNVs as risk factors in cancer,
including neuroblastoma [19], colorectal cancer [22,23],
hepatocellular carcinoma [44], aggressive prostate cancer
[20], nasopharyngeal carcinoma[45]and BRCA1-asso-
ciated ovarian cancer[38]. Our findings of a possible
association of a cancer predisposition phenotype with
rare CNVs affecting different genes are in line with the
genetic heterogeneity reported in breast cancer. This
picture is different from most of the aforementioned
studies, which detected recurrent common CNVs asso-
ciated with cancer risk, except for prostate, colorectal
and ovarian cancer CNV studies, which exhibited high
CNV heterogeneity.
Conclusions
Our analysis of rare CNVs in a small cohort of BRCA1/
BRCA2 mutation-negative breast and/or ovarian cancer
families suggests an intriguing excess in the proportion
of rare CNVs compared to controls. The future chal-
lenge will be to expand sample sizes and to follow cose-
gregation of given CNVs with cancer phenotype within
families to identify which of the genes involved in the
rare CNVs might contribute to familial breast cancer
predisposition.
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positions (build 36-Hg18), mapping, type and affected genes of the 23
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